A concomitant medication is any drug a person takes alongside their primary treatment. The term comes up most often in clinical trials, where it refers to medications a participant uses that are not the drug being studied. But it applies broadly in everyday medicine too: if you take blood pressure medication and your doctor prescribes an antibiotic for an infection, the blood pressure medication is concomitant to the antibiotic treatment, and vice versa.
Why the Term Matters in Clinical Trials
In clinical research, tracking every medication a participant takes is essential. The National Cancer Institute defines a concomitant medication as one “not being studied in the clinical trial” that the participant is taking. Researchers need to know about these drugs because they can interfere with results in two major ways: they can make the experimental drug appear more or less effective than it actually is, or they can increase the risk of side effects.
International guidelines for good clinical practice require that trial protocols spell out which medications are permitted and which are not permitted before or during a study. Every concomitant drug a participant takes gets logged, typically with its dose, schedule, and the reason it was prescribed. This documentation helps researchers untangle whether a side effect came from the study drug or from something else the patient was already taking.
How Concomitant Drugs Interact With Each Other
The biggest concern with concomitant medications is drug interactions. Your body processes most drugs through a family of liver enzymes called CYP450. When two drugs pass through the same enzyme pathway, one can speed up or slow down the breakdown of the other, changing how much active drug ends up in your bloodstream.
The effects can be dramatic. In heart transplant patients taking cyclosporine (an immune-suppressing drug), blood levels of a common cholesterol medication rose more than sevenfold compared to people taking the cholesterol drug alone. The cyclosporine was blocking a transporter protein that normally carries the cholesterol drug into liver cells for processing.
Interactions don’t only happen in the liver. In the kidneys, one drug can block the channels that another drug uses to get filtered out of the body. The antibiotic clarithromycin, for example, reduces the kidney’s ability to clear the heart medication digoxin by blocking a transport protein in kidney cells. The cholesterol drug gemfibrozil does something similar to pravastatin, doubling the amount of pravastatin in the body and raising the risk of muscle damage.
Even the gut plays a role. Drugs or foods can inhibit enzymes and transport proteins in the intestinal lining, changing how much of a medication gets absorbed in the first place. This is why some trial protocols require participants to fast for several hours before and after taking an experimental drug, and why medications that alter stomach acid levels (like antacids or proton pump inhibitors) are often restricted.
Which Medications Get Restricted in Trials
Not all concomitant medications are allowed during a clinical trial. Researchers evaluate each drug class for potential interactions with the experimental treatment and decide whether to permit, restrict, or prohibit it. The most commonly excluded categories, based on an analysis of pancreatic cancer trials, were antibiotics (excluded in about 35% of trials), other anti-infective agents (29%), antifungal drugs (26%), and blood thinners (18%).
A separate analysis of trials at a major cancer center found that corticosteroids were the single most commonly excluded medication class, restricted in 60% of protocols. Antifungals came next at 36%, followed by blood thinners at 15%.
Nearly half of the 102 trials in that analysis excluded drugs that interact with the CYP3A4 enzyme pathway, one of the most active drug-processing enzymes in the body. The strictness of these exclusions varies considerably. Some protocols flatly prohibit any strong CYP3A4 inhibitor or inducer. Others use softer language, saying such drugs are “not recommended” but can be used “with caution” if medically necessary.
These restrictions sometimes go further than the science supports. A joint working group from the American Society of Clinical Oncology and Friends of Cancer Research highlighted a common example: many trial protocols ban the anti-nausea drug ondansetron entirely because of concerns about heart rhythm changes. In practice, that risk applies only to high-dose intravenous ondansetron, not the oral form that patients commonly use. Overly broad exclusions like this can prevent otherwise eligible patients from enrolling in trials.
Concomitant Medications and Side Effect Reporting
When a participant in a clinical trial experiences a side effect, researchers need to figure out what caused it. Was it the experimental drug, a concomitant medication, or the underlying disease? Several standardized tools exist for this purpose. The World Health Organization’s causality framework, for instance, specifically evaluates whether “other competing causes such as medications or diseases” could explain the reaction. The widely used Naranjo Scale includes a question about alternative causes and subtracts points from the causal link to the study drug if another medication could be responsible.
This matters for patients because it shapes how side effects get reported on drug labels. If concomitant medications aren’t carefully tracked, a side effect caused by a drug interaction might be incorrectly attributed to the experimental treatment alone, or missed entirely.
Concomitant Medications in Everyday Medicine
Outside of clinical trials, concomitant medications are a routine reality for millions of people. Anyone managing more than one health condition takes concomitant drugs. The challenge grows with age: older adults commonly take five or more medications at once, a situation called polypharmacy, which multiplies the opportunities for interactions.
The same interaction mechanisms that concern clinical researchers apply in your medicine cabinet. Two drugs metabolized by the same liver enzyme can interfere with each other. A new prescription can change how well an existing medication works. Even over-the-counter drugs and supplements, which are prescribed in up to 55% of cancer patients, can alter how the body absorbs or processes other medications.
Practical strategies for managing multiple medications include comprehensive medication reviews, where a pharmacist or doctor evaluates every drug you take for potential conflicts. Tools like the Beers Criteria help identify medications that are particularly risky for older adults. Electronic health records can flag interactions automatically when a new prescription is entered. The simplest step is keeping an updated list of everything you take, including supplements and over-the-counter products, and sharing it with every provider who prescribes for you.
Why Concomitant Medications Can Skew Research Results
Beyond safety, concomitant medications can quietly distort the conclusions of a study. A large analysis of breast cancer patients published in Nature Communications found that medications targeting the nervous system had strikingly different associations with survival depending on the specific drug. Among benzodiazepines (a class of anti-anxiety medications), one formulation was associated with a modest survival benefit while another was linked to worse outcomes. Without carefully tracking which patients were taking which concomitant drugs, these opposing effects would have been invisible in the data, potentially canceling each other out or creating misleading averages.
This is why clinical trial protocols devote significant space to concomitant medication rules. Every pill a participant takes is a variable that could cloud the picture of whether the experimental treatment actually works.